Summary by Futu AI
SeaStar Medical Holding Corporation, a medical technology company, has entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, dated August 20, 2024. Under the agreement, SeaStar Medical may offer and sell up to $25 million of its common stock from time to time through Wainwright. The sales may be made on the Nasdaq Capital Market or other existing trading markets in the United States. Wainwright will act as a sales agent and will use commercially reasonable efforts to sell the shares on behalf of SeaStar Medical. The offering will terminate upon the termination of the agreement by either SeaStar Medical or Wainwright. This move comes after SeaStar Medical's recent developments, including the receipt of an approvable letter from the FDA for its Selective Cytopheretic Device (SCD) for pediatric use and the initiation of a pivotal trial for the SCD in adult patients with acute kidney injury. The company's common stock and warrants are traded on Nasdaq under the symbols 'ICU' and 'ICUCW,' respectively.
